Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Feb 27, 2020SANTA BARBARA, Calif., Feb 27, 2020 -- Direct Relief, BD (Becton, Dickinson and Company) and the National Association of Free & Charitable Clinics (NAFC) today announced $125,000 in funding for...
Feb 20, 2020FRANKLIN LAKES, N.J., February 20, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD Synapsys™ microbiology...
Feb 17, 2020BD Kiestra™ ReadA is device listed with the U.S. FDAFRANKLIN LAKES, N.J., February 17, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the BD Kiestra™ ReadA is device...
Feb 13, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new, $6 million contract with the Fleming Fund, a U.K. aid program that helps low-...
-
Feb 12, 2020New capillary blood collection device combined with innovative sample handling and analytical technologies in clinical studies aim to make diagnostic blood testing more accessible and convenient
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company and Babson Diagnostics, a transformative diagnostic blood testing company, today announced a long-term...
-
Feb 11, 2020
FRANKLIN LAKES, N.J. (Feb. 11, 2020) – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the completion of a 50-subject human clinical trial with...
Feb 6, 2020- As reported, revenues of $4.225 billion increased 1.6 percent.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.225 billion for the first fiscal quarter ended December 31,...
-
Jan 29, 2020Three-year mortality and amputation data for Lutonix® 014 Drug-Coated Balloon Below-The-Knee IDE trial presented at LINC
FRANKLIN LAKES, N.J. (Jan. 29, 2020) – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced that interim findings from the Lutonix below-the-knee...
-
Jan 27, 2020
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 per common share, payable on March 31, 2020 to holders of record on March 10,...
-
Jan 23, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday,...
-
Jan 17, 2020
The meta-analysis published by Dr. Konstantinos Katsanos, et al in the Journal of Vascular and Interventional Radiology on January 14 focused on amputation-free survival (defined as freedom from...
-
Jan 9, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2020 earnings conference call on Thursday, February 6, 2020, at 8:00...
Jan 3, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday,...
Nov 25, 2019The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 cents per common share, an increase of 2.6 percent from the previous quarter....
-
Nov 22, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday,...
Nov 21, 2019New antimicrobial stewardship technology will be demonstrated at ASHP 2019 Midyear MeetingBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its latest advancement in combating antimicrobial resistance (AMR) with new analytics...
-
Nov 18, 2019BD Kiestra™ IdentifA system is available in Europe (CE marked) and Canada
FRANKLIN LAKES, NJ (November 18, 2019) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced availability in Europe (CE marked) and...
-
Nov 15, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it has been notified of an unsolicited mini-tender offer by TRC Capital Investment Corporation ("TRC") to purchase up to 500,000...
Nov 14, 2019BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Jefferies 2019 London Healthcare Conference on Thursday,...
Nov 12, 2019BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug...
-
Nov 5, 2019- As reported, full fiscal year revenues of $17.290 billion increased 8.2 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.584 billion for the fourth fiscal quarter ended September 30,...
-
Oct 29, 2019
FRANKLIN LAKES, N.J., and WAGENINGEN, THE NETHERLANDS, October 29, 2019 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points...
-
Oct 28, 2019BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit is designed and tested to work with BD Rhapsody™ Single-Cell Analysis System, BD® AbSeq reagents and BD® Single-Cell Multiplexing Kit
Franklin Lakes, N.J., October 28, 2019 – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the availability of BD Rhapsody WTA Amplification kit...
-
Oct 3, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2019 earnings conference call on Tuesday,...
-
Sep 28, 2019Independent analysis of LUTONIX® 035 Drug Coated Balloon patient-level data showed no statistically significant mortality increase
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a company-initiated, independent analysis of the LUTONIX® 035 Drug...